title: Should women receiving tamoxifen be screened for endometrial cancer? An argument for screening.
authors: Department of Obstetrics and Gynecology, North Shore University Hospital, North Shore-Long Island Jewish Health System, Manhasset, New York, USA.
authors: A W
authors: AW
authors: Menzin
authors: D
authors: D
authors: Gal
authors: R R
authors: RR
authors: Barakat
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000517:prevention & control; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D020847:Estrogen Receptor Modulators / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008403:Mass Screening; D011159:Population Surveillance; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen